Related Experiment Video
Updated: Dec 7, 2025
Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors
Published on: September 20, 2016
EGFR exon 20 insertions in advanced non-small cell lung cancer: A new history begins
Jordi Remon1, Lizza E L Hendriks2, Andres F Cardona3
1Department of Medical Oncology, Centro Integral Oncológico Clara Campal (HM-CIOCC), Hospital HM Delfos, HM Hospitales, Barcelona, Spain.
Abstract:
Although targeted therapy is standard of care in a large subset of oncogenic addicted non-small cell lung cancers (NSCLC), until recently, this therapeutic approach has not been feasible for all genomic alterations such as for those tumors harboring Epidermal Growth Factor Receptor (EGFR) exon 20 insertion (ex20ins) mutations. Despite being the third most common EGFR mutation, a limited efficacy of first- and second-generation EGFR tyrosine kinase inhibitors (TKI) exists. This is related to the heterogeneity at the molecular level in EGFR ex20ins mutation variants and the finding that this mutation promotes active kinase conformation but does not increase the affinity for EGFR TKI. As a result, the prognosis of this population is diminished. Therefore, chemotherapy remained the most suitable strategy in this subset of EGFR mutant NSCLC patients. Recently, new treatment strategies have been reported in this landscape, either with new EGFR TKI or bispecific antibodies, which may establish a new standard of care in the coming future for these patients. Future research should focus on elucidating the oncogenic degree of all EGFR ex20ins variants, the potential role of combination strategies either with chemotherapy or immune checkpoint inhibitors, and the most appropriate first-line treatment strategy in this subgroup. Finally, the knowledge of mechanisms of acquired resistance to these new agents upon progression is a priority for personalising treatment at that time. It is in this framework, that we provide a thorough overview on this subject.
Insights
New treatments are emerging for non-small cell lung cancer (NSCLC) with Epidermal Growth Factor Receptor (EGFR) exon 20 insertion mutations, offering hope where traditional therapies were limited. Research is ongoing to optimize these novel strategies for better patient outcomes.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Non-small cell lung cancer (NSCLC) with Epidermal Growth Factor Receptor (EGFR) exon 20 insertion (ex20ins) mutations presents a therapeutic challenge.
- Traditional EGFR tyrosine kinase inhibitors (TKIs) show limited efficacy due to molecular heterogeneity and altered kinase conformation.
- Chemotherapy has been the primary treatment, but novel therapeutic strategies are now being investigated.
Purpose of the Study:
- To provide a comprehensive overview of treatment strategies for NSCLC patients with EGFR ex20ins mutations.
- To discuss the limitations of existing therapies and the potential of emerging treatments.
- To highlight future research directions for optimizing care in this patient subgroup.
Main Methods:
- Review of current literature on EGFR ex20ins mutations in NSCLC.
- Analysis of the efficacy and limitations of existing and novel therapeutic agents.
- Discussion of ongoing research and future directions in treatment strategies.
Main Results:
- EGFR ex20ins mutations are associated with poor prognosis and resistance to conventional EGFR TKIs.
- New EGFR TKIs and bispecific antibodies show promise in preclinical and early clinical studies.
- Understanding oncogenic drivers and resistance mechanisms is crucial for treatment personalization.
Conclusions:
- Novel therapeutic approaches, including new EGFR TKIs and bispecific antibodies, are emerging for NSCLC with EGFR ex20ins mutations.
- Further research is needed to elucidate the oncogenic potential of different ex20ins variants and optimize combination strategies.
- Personalized treatment strategies, including understanding acquired resistance mechanisms, are essential for improving patient outcomes.
More Related Videos
07:59Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
Published on: September 8, 2023
09:38Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
Published on: August 11, 2017
Related Concept Videos
02:38Mitogens and the Cell Cycle
03:18Non-LTR Retrotransposons
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...